Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation.
BRUXISM
COST–BENEFIT ANALYSIS
QUALITY OF LIFE
QUALITY-ADJUSTED LIFE-YEARS
SPLINTS
TEMPOROMANDIBULAR JOINT DISORDERS
Journal
Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
18
2
2020
pubmed:
18
2
2020
medline:
13
5
2021
Statut:
ppublish
Résumé
Splints are a non-invasive, reversible management option for temporomandibular disorders or bruxism. The clinical effectiveness and cost-effectiveness of splints remain uncertain. The objectives were to evaluate the clinical effectiveness and cost-effectiveness of splints for patients with temporomandibular disorders or bruxism. This evidence synthesis compared (1) all types of splint versus no/minimal treatment/control splints and (2) prefabricated versus custom-made splints, for the primary outcomes, which were pain (temporomandibular disorders) and tooth wear (bruxism). Four databases, including MEDLINE and EMBASE, were searched from inception until 1 October 2018 for randomised clinical trials. The searches were conducted on 1 October 2018. Cochrane review methods (including risk of bias) were used for the systematic review. Standardised mean differences were pooled for the primary outcome of pain, using random-effects models in temporomandibular disorder patients. A Markov cohort, state-transition model, populated using current pain and Characteristic Pain Intensity data, was used to estimate the incremental cost-effectiveness ratio for splints compared with no splint, from an NHS perspective over a lifetime horizon. A value-of-information analysis identified future research priorities. Fifty-two trials were included in the systematic review. The evidence identified was of very low quality with unclear reporting by temporomandibular disorder subtype. When all subtypes were pooled into one global temporomandibular disorder group, there was no evidence that splints reduced pain [standardised mean difference (at up to 3 months) -0.18, 95% confidence interval -0.42 to 0.06; substantial heterogeneity] when compared with no splints or a minimal intervention. There was no evidence that other outcomes, including temporomandibular joint noises, decreased mouth-opening, and quality of life, improved when using splints. Adverse events were generally not reported, but seemed infrequent when reported. The most plausible base-case incremental cost-effectiveness ratio was uncertain and driven by the lack of clinical effectiveness evidence. The cost-effectiveness acceptability curve showed splints becoming more cost-effective at a willingness-to-pay threshold of ≈£6000, but the probability never exceeded 60% at higher levels of willingness to pay. Results were sensitive to longer-term extrapolation assumptions. A value-of-information analysis indicated that further research is required. There were no studies measuring tooth wear in patients with bruxism. One small study looked at pain and found a reduction in the splint group [mean difference (0-10 scale) -2.01, 95% CI -1.40 to -2.62; very low-quality evidence]. As there was no evidence of a difference between splints and no splints, the second objective became irrelevant. There was a large variation in the diagnostic criteria, splint types and outcome measures used and reported. Sensitivity analyses based on these limitations did not indicate a reduction in pain. The very low-quality evidence identified did not demonstrate that splints reduced pain in temporomandibular disorders as a group of conditions. There is insufficient evidence to determine whether or not splints reduce tooth wear in patients with bruxism. There remains substantial uncertainty surrounding the most plausible incremental cost-effectiveness ratio. There is a need for well-conducted trials to determine the clinical effectiveness and cost-effectiveness of splints in patients with carefully diagnosed and subtyped temporomandibular disorders, and patients with bruxism, using agreed measures of pain and tooth wear. This study is registered as PROSPERO CRD42017068512. This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Treatment options for people experiencing temporomandibular disorders (pain and/or restricted movement in and around the jaw joint) include splints, which are removable appliances, often similar to a mouthguard. They are provided to patients to help ease pain in the mouth, face or jaws. They are also used to manage the symptoms of temporomandibular disorders, such as frequent headaches/migraines, clicking jaws, restricted mouth-opening or tooth wear from the grinding of teeth (bruxism). There are many types of splints. This research looked at the evidence addressing the primary question of whether or not splints work (regardless of type of splint) in reducing the pain associated with temporomandibular disorders and/or tooth wear, and if they offered value for money. Patients were involved in the research to ensure that the question and the outcomes that were measured were appropriate. A systematic review of the literature was undertaken to find all randomised controlled trials including patients with temporomandibular disorders or bruxism. Online databases of research publications were searched, and these searches were checked, to identify relevant trials. All stages of the review process were undertaken to the highest standards by two people, independently and in duplicate, using well-respected and recognised Cochrane methods. We conducted a value-for-money assessment, comparing the trial data with the costs of splints to see if splints are a cost-effective use of NHS funding. There was no evidence that splints reduced pain when compared with not wearing a splint or when compared with a minimal treatment (like jaw exercises, advice or education) in patients with temporomandibular disorders. The evidence was assessed as being of very low quality; therefore, it remains unclear whether or not splints are good value for money, or if they should be paid for by the NHS. This research showed that more well-conducted trials on temporomandibular disorder patients are needed.
Sections du résumé
BACKGROUND
Splints are a non-invasive, reversible management option for temporomandibular disorders or bruxism. The clinical effectiveness and cost-effectiveness of splints remain uncertain.
OBJECTIVES
The objectives were to evaluate the clinical effectiveness and cost-effectiveness of splints for patients with temporomandibular disorders or bruxism. This evidence synthesis compared (1) all types of splint versus no/minimal treatment/control splints and (2) prefabricated versus custom-made splints, for the primary outcomes, which were pain (temporomandibular disorders) and tooth wear (bruxism).
REVIEW METHODS
Four databases, including MEDLINE and EMBASE, were searched from inception until 1 October 2018 for randomised clinical trials. The searches were conducted on 1 October 2018. Cochrane review methods (including risk of bias) were used for the systematic review. Standardised mean differences were pooled for the primary outcome of pain, using random-effects models in temporomandibular disorder patients. A Markov cohort, state-transition model, populated using current pain and Characteristic Pain Intensity data, was used to estimate the incremental cost-effectiveness ratio for splints compared with no splint, from an NHS perspective over a lifetime horizon. A value-of-information analysis identified future research priorities.
RESULTS
Fifty-two trials were included in the systematic review. The evidence identified was of very low quality with unclear reporting by temporomandibular disorder subtype. When all subtypes were pooled into one global temporomandibular disorder group, there was no evidence that splints reduced pain [standardised mean difference (at up to 3 months) -0.18, 95% confidence interval -0.42 to 0.06; substantial heterogeneity] when compared with no splints or a minimal intervention. There was no evidence that other outcomes, including temporomandibular joint noises, decreased mouth-opening, and quality of life, improved when using splints. Adverse events were generally not reported, but seemed infrequent when reported. The most plausible base-case incremental cost-effectiveness ratio was uncertain and driven by the lack of clinical effectiveness evidence. The cost-effectiveness acceptability curve showed splints becoming more cost-effective at a willingness-to-pay threshold of ≈£6000, but the probability never exceeded 60% at higher levels of willingness to pay. Results were sensitive to longer-term extrapolation assumptions. A value-of-information analysis indicated that further research is required. There were no studies measuring tooth wear in patients with bruxism. One small study looked at pain and found a reduction in the splint group [mean difference (0-10 scale) -2.01, 95% CI -1.40 to -2.62; very low-quality evidence]. As there was no evidence of a difference between splints and no splints, the second objective became irrelevant.
LIMITATIONS
There was a large variation in the diagnostic criteria, splint types and outcome measures used and reported. Sensitivity analyses based on these limitations did not indicate a reduction in pain.
CONCLUSIONS
The very low-quality evidence identified did not demonstrate that splints reduced pain in temporomandibular disorders as a group of conditions. There is insufficient evidence to determine whether or not splints reduce tooth wear in patients with bruxism. There remains substantial uncertainty surrounding the most plausible incremental cost-effectiveness ratio.
FUTURE WORK
There is a need for well-conducted trials to determine the clinical effectiveness and cost-effectiveness of splints in patients with carefully diagnosed and subtyped temporomandibular disorders, and patients with bruxism, using agreed measures of pain and tooth wear.
STUDY REGISTRATION
This study is registered as PROSPERO CRD42017068512.
FUNDING
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in
Treatment options for people experiencing temporomandibular disorders (pain and/or restricted movement in and around the jaw joint) include splints, which are removable appliances, often similar to a mouthguard. They are provided to patients to help ease pain in the mouth, face or jaws. They are also used to manage the symptoms of temporomandibular disorders, such as frequent headaches/migraines, clicking jaws, restricted mouth-opening or tooth wear from the grinding of teeth (bruxism). There are many types of splints. This research looked at the evidence addressing the primary question of whether or not splints work (regardless of type of splint) in reducing the pain associated with temporomandibular disorders and/or tooth wear, and if they offered value for money. Patients were involved in the research to ensure that the question and the outcomes that were measured were appropriate. A systematic review of the literature was undertaken to find all randomised controlled trials including patients with temporomandibular disorders or bruxism. Online databases of research publications were searched, and these searches were checked, to identify relevant trials. All stages of the review process were undertaken to the highest standards by two people, independently and in duplicate, using well-respected and recognised Cochrane methods. We conducted a value-for-money assessment, comparing the trial data with the costs of splints to see if splints are a cost-effective use of NHS funding. There was no evidence that splints reduced pain when compared with not wearing a splint or when compared with a minimal treatment (like jaw exercises, advice or education) in patients with temporomandibular disorders. The evidence was assessed as being of very low quality; therefore, it remains unclear whether or not splints are good value for money, or if they should be paid for by the NHS. This research showed that more well-conducted trials on temporomandibular disorder patients are needed.
Autres résumés
Type: plain-language-summary
(eng)
Treatment options for people experiencing temporomandibular disorders (pain and/or restricted movement in and around the jaw joint) include splints, which are removable appliances, often similar to a mouthguard. They are provided to patients to help ease pain in the mouth, face or jaws. They are also used to manage the symptoms of temporomandibular disorders, such as frequent headaches/migraines, clicking jaws, restricted mouth-opening or tooth wear from the grinding of teeth (bruxism). There are many types of splints. This research looked at the evidence addressing the primary question of whether or not splints work (regardless of type of splint) in reducing the pain associated with temporomandibular disorders and/or tooth wear, and if they offered value for money. Patients were involved in the research to ensure that the question and the outcomes that were measured were appropriate. A systematic review of the literature was undertaken to find all randomised controlled trials including patients with temporomandibular disorders or bruxism. Online databases of research publications were searched, and these searches were checked, to identify relevant trials. All stages of the review process were undertaken to the highest standards by two people, independently and in duplicate, using well-respected and recognised Cochrane methods. We conducted a value-for-money assessment, comparing the trial data with the costs of splints to see if splints are a cost-effective use of NHS funding. There was no evidence that splints reduced pain when compared with not wearing a splint or when compared with a minimal treatment (like jaw exercises, advice or education) in patients with temporomandibular disorders. The evidence was assessed as being of very low quality; therefore, it remains unclear whether or not splints are good value for money, or if they should be paid for by the NHS. This research showed that more well-conducted trials on temporomandibular disorder patients are needed.
Identifiants
pubmed: 32065109
doi: 10.3310/hta24070
pmc: PMC7049908
doi:
Types de publication
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-224Subventions
Organisme : Department of Health
ID : 16/146/06
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Department of Health
ID : HTA/16/146/06
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR-CS-011-003
Pays : United Kingdom
Déclaration de conflit d'intérêts
No competing interests were declared.
Références
Head Face Med. 2013 Jan 25;9:5
pubmed: 23351923
Pain. 2005 Jan;113(1-2):9-19
pubmed: 15621359
J Appl Oral Sci. 2005 Dec;13(4):345-50
pubmed: 20865217
Acta Odontol Scand. 2012 Jan;70(1):72-7
pubmed: 21728748
J Oral Rehabil. 2002 Dec;29(12):1181-6
pubmed: 12472855
J Jpn Phys Ther Assoc. 2015;18(1):1-6
pubmed: 26733760
J Oral Rehabil. 2012 Nov;39(11):799-804
pubmed: 22809314
Br Dent J. 2004 Jul 10;197(1):35-41; discussion 31; quiz 50-1
pubmed: 15243608
Endokrynol Pol. 2014;65(3):217-23
pubmed: 24971923
J Am Dent Assoc. 2013;144(10):1154-63
pubmed: 24080932
Cranio. 2006 Oct;24(4):258-64
pubmed: 17086855
J Biol Regul Homeost Agents. 2013 Oct-Dec;27(4):1011-9
pubmed: 24382182
BMJ. 2003 Apr 26;326(7395):911
pubmed: 12714472
J Orofac Pain. 2005 Spring;19(2):151-8
pubmed: 15895838
J Oral Sci. 2011 Sep;53(3):349-54
pubmed: 21959663
BMJ. 1996 Aug 3;313(7052):275-83
pubmed: 8704542
J Orofac Pain. 2013 Spring;27(2):99-110
pubmed: 23630682
J Appl Oral Sci. 2015 Oct;23(5):529-35
pubmed: 26200526
J Am Dent Assoc. 2001 Mar;132(3):305-16
pubmed: 11258087
J Oral Rehabil. 2019 Jan;46(1):1-4
pubmed: 30203622
Acta Odontol Scand. 1991 Jun;49(3):153-8
pubmed: 1882649
J Oral Rehabil. 2012 Jul;39(7):489-501
pubmed: 22489928
J Orofac Pain. 2008 Summer;22(3):209-18
pubmed: 18780534
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Int J Oral Maxillofac Surg. 2008 May;37(5):424-7
pubmed: 18356022
J Oral Rehabil. 2003 Feb;30(2):113-8
pubmed: 12535135
Cranio. 2018 Sep;36(5):327-331
pubmed: 28697676
Arch Oral Biol. 2015 May;60(5):738-44
pubmed: 25768709
J Adv Prosthodont. 2014 Apr;6(2):103-8
pubmed: 24843394
Swed Dent J. 1992;16(4):125-41
pubmed: 1455324
Prim Dent Care. 2000 Jul;7(3):109-13
pubmed: 11404899
J Indian Prosthodont Soc. 2014 Sep;14(3):251-61
pubmed: 25183909
Acta Odontol Scand. 2016 Aug;74(6):480-6
pubmed: 27410169
Trials. 2016 Sep 13;17(1):449
pubmed: 27618914
Cranio. 2010 Oct;28(4):249-59
pubmed: 21032979
J Oral Rehabil. 2009 Feb;36(2):79-85
pubmed: 18976268
J Oral Rehabil. 2009 Aug;36(8):547-55
pubmed: 19604318
Br Dent J. 2020 Feb;228(3):191-197
pubmed: 32060462
Chiropr Man Therap. 2014 Dec 15;22(1):43
pubmed: 25512839
J Pain. 2008 Feb;9(2):105-21
pubmed: 18055266
J Dent Res. 2010 Nov;89(11):1259-63
pubmed: 20739691
Oral Surg Oral Med Oral Pathol. 1985 Aug;60(2):131-6
pubmed: 3862019
J Oral Rehabil. 2012 Oct;39(10):754-60
pubmed: 22672361
J Appl Oral Sci. 2006 Jan;14(1):61-6
pubmed: 19089032
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
J Oral Rehabil. 2013 Jan;40(1):2-4
pubmed: 23121262
Gen Dent. 1987 Nov-Dec;35(6):502-6
pubmed: 3481734
J Orofac Pain. 1995 Spring;9(2):192-9
pubmed: 7488989
Med Decis Making. 2005 Nov-Dec;25(6):633-45
pubmed: 16282214
J Orofac Pain. 2003 Spring;17(2):133-9
pubmed: 12836501
Value Health. 2010 Aug;13(5):509-18
pubmed: 20230546
J Oral Rehabil. 2008 Jul;35(7):495-508
pubmed: 18557916
J Am Dent Assoc. 2006 Aug;137(8):1099-107; quiz 1169
pubmed: 16873325
J Dent Res. 1988 Mar;67(3):597-601
pubmed: 3170898
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Indian Prosthodont Soc. 2016 Apr-Jun;16(2):176-81
pubmed: 27141168
Appl Health Econ Health Policy. 2015 Apr;13(2):167-79
pubmed: 25650349
BMC Oral Health. 2014 Jan 21;14:6
pubmed: 24447722
Acta Odontol Scand. 1998 Apr;56(2):122-8
pubmed: 9669465
Br Dent J. 2014 Jun 13;216(11):E24
pubmed: 24923962
Cephalalgia. 2013 Nov;33(15):1248-57
pubmed: 23771211
Acta Odontol Scand. 2016;74(2):134-41
pubmed: 26139326
JAMA. 2013 Jun 5;309(21):2217-8
pubmed: 23736731
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158
pubmed: 15361314
Pain. 1994 Jan;56(1):85-94
pubmed: 8159444
J Dent Res. 2016 Sep;95(10):1147-54
pubmed: 27154734
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
Int J Oral Maxillofac Surg. 2017 May;46(5):603-609
pubmed: 28222947
Chin Med J (Engl). 2013 Jun;126(12):2270-5
pubmed: 23786937
Oral Surg Oral Med Oral Pathol. 1988 Aug;66(2):155-62
pubmed: 3174047
Oral Surg Oral Med Oral Pathol. 1992 Jun;73(6):655-8
pubmed: 1437030
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
J Oral Rehabil. 2015 Sep;42(9):643-50
pubmed: 25818477
J Craniomandib Disord. 1992 Fall;6(4):301-55
pubmed: 1298767
Pain. 2010 May;149(2):354-9
pubmed: 20304556
Curr Treat Options Neurol. 2006 Jan;8(1):69-79
pubmed: 16343362
J Dent. 2001 Sep;29(7):451-67
pubmed: 11809323
Nature. 2018 Mar 7;555(7695):175-182
pubmed: 29517004
Sven Tandlak Tidskr. 1974 Mar;67(2):101-21
pubmed: 4524733
J Am Dent Assoc. 2006 Aug;137(8):1108-14
pubmed: 16873326
Acta Odontol Scand. 2003 Aug;61(4):203-11
pubmed: 14582587
Swed Dent J Suppl. 2015;(238):10-72
pubmed: 26939312
J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2 Suppl. 2):21-29
pubmed: 29720327
Egypt Dent J. 1995 Jul;41(3):1227-32
pubmed: 9497660
Acta Odontol Scand. 2011 May;69(3):129-36
pubmed: 21142584
Pain. 1992 Aug;50(2):133-49
pubmed: 1408309
J Oral Rehabil. 2015 Dec;42(12):890-9
pubmed: 26174571
Cranio. 2012 Jul;30(3):172-82
pubmed: 22916669
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):741-7
pubmed: 16731393
Laryngoscope. 2014 Oct;124(10):2427-32
pubmed: 24458949
J Oral Rehabil. 2017 Aug;44(8):589-593
pubmed: 28593734
Swed Dent J. 1999;23(1):27-37
pubmed: 10371003
J Am Dent Assoc. 2012 Jan;143(1):47-53
pubmed: 22207667
J Oral Facial Pain Headache. 2014 Spring;28(2):128-37
pubmed: 24822236
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Feb;107(2):212-23
pubmed: 19138639
J Oral Facial Pain Headache. 2014 Winter;28(1):6-27
pubmed: 24482784